{"id":"W2117964602","doi":"10.1016/s1470-2045(11)70214-5","title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1113,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; Juravinski Cancer Centre; Vancouver General Hospital; Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal; Université de Montréal; BC Cancer Agency; Princess Margaret Cancer Centre; Jewish General Hospital","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Internal medicine; Tolerability; Breast cancer; Ovarian cancer; Oncology; BRCA mutation; PARP inhibitor; Clinical endpoint; Triple-negative breast cancer; Adverse effect; Response Evaluation Criteria in Solid Tumors; Cancer; Serous fluid; Phases of clinical research; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001518688,0.00164626,0.003119019,0.0003678015,0.0003383737,0.001309311,0.0006725653,0.001515906,0.002947871],"category_scores_gemma":[0.002001887,0.000702781,0.002391229,0.0005405281,0.001074727,0.001339738,0.0004801437,0.002680496,0.000673212],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000652259,"about_ca_system_score_gemma":0.000742389,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007898663,"about_ca_topic_score_gemma":0.001385797,"domain_scores_codex":[0.9992493,0.0004014163,0.00005028744,0.0001283676,0.00005859277,0.0001120569],"domain_scores_gemma":[0.9990572,0.0003467516,0.0002043744,0.00009641634,0.00004252171,0.0002526743],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.968868,0.003447413,0.002909726,0.0006636194,0.001586037,0.0001128347,0.00008157673,0.0004786997,0.00261835,0.00006752579,0.000528466,0.0186378],"study_design_scores_gemma":[0.9204349,0.06985808,0.006698267,0.00003693797,0.001100742,0.0001336994,0.00005471263,0.0004784024,0.0002872969,0.0001777412,0.0007094108,0.00002987268],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927713,0.004122259,0.0003686535,0.0004076777,0.0002114368,0.0006877633,0.0006363013,0.00004401532,0.0007503881],"genre_scores_gemma":[0.992995,0.002809852,0.0005907576,0.0007372315,0.0002237249,0.0007170221,0.0008505413,0.00001586107,0.001060071],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003119019,"threshold_uncertainty_score":0.009861588,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1110609224459381,"score_gpt":0.3838345029660907,"score_spread":0.2727735805201525,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}